Table 3. Molecular Characteristics of Triple Negative Breast Cancers (n = 105).
| Number of cases (%) | EGFR copy number change | EGFR mutation | KRAS mutation | TP53 mutation |
| 61 (58.1%) | N | − | − | − |
| 25 (23.8%) | N | − | − | + |
| 2 (1.9%) | N | − | + a | + |
| 1 (1.0%) | N | + b | − | − |
| 6 (5.7%) | I | − | − | − |
| 5 (4.8%) | I | − | − | + |
| 2 (1.9%) | I† | − | − | − |
| 2 (1.9%) | D | − | − | − |
| 1 (1.0%) | D | − | − | + |
| 105 | 1 (1.0%) | 2 (1.9%) | 33 (31.4%) |
'−', wild type; '+', mutant type; 'D', decreased copy number (hemizygous deletion); ‘N’, normal copy number; 'I', increased EGFR copy number (single copy gain, amplification and high-copy number amplification); † single exon amplification; a p.Gly12Val and p.Gly12Asp; b Deletion on Exon 19. BRAF gene mutation was not detected in all cases